Patients with autoimmune inflammatory rheumatic diseases had an increased risk of testing positive for SARS-CoV-2 and worse clinical outcomes of COVID-19, including death, although disease-modifying antirheumatic drugs (DMARDs) did not increase the risk of these outcomes.
Claire Daien, MD, discusses the safety and efficacy of ABX464, the primary and secondary endpoints, and what differentiates the medication from other rheumatoid arthritis therapies.
Chronic pain and functional limitations, along with these academic and social difficulties, are directly related to mental health complaints. Therefore, adolescents with rheumatic diseases are at a higher risk for developing mental illness.
Methotrexate has been the mainstay treatment for mild to moderate arthritis for many years, and the recent update to the American College of Rheumatology Guidelines on the Management of Rheumatoid Arthritis aims to maximize the use of methotrexate before advancing to a biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD). With this in mind, it is important to be up-to-speed on initiating methotrexate in patients with rheumatoid arthritis. Test your knowledge with this quiz.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 2, 2021.
The investigators linked immediate biological responses and symptomatic and structural outcomes to long-term injuries in active patients.
The US Food and Drug Administration (FDA) has delayed its decision on upadacitinib (RINVOQ) for the for the treatment of adults with active psoriatic arthritis and adults with active ankylosing spondylitis.
Test your knowledge of the treatment and management of rheumatoid arthritis (RA) with our RA quizzes.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 25, 2021.
In patients with early inflammatory arthritis, a serum protein biomarker panel was proven effective in separating patients with psoriatic arthritis from those with rheumatoid arthritis.
Researchers cite a lack of knowledge on the disease and treatments, which they believe affect the quality of life of patients.
An SMS-based, interactive, educational video greatly increased information related to COVID-19 vaccines, confidence in vaccine safety, and an inclination to receive the vaccine.
Investigators report on the implications of ethnicity and rheumatic diseases on South Korean patients with COVID-19.
The American College of Rheumatology has updated its treatment guidelines for the management of pediatric rheumatic disease during the COVID-19 pandemic. The guideline includes 33 final guidance recommendations, 8 of which received moderate-to-high task force consensus.
Upadacitinib (UPA) effectively treated patients with psoriatic arthritis (PsA) and axial involvement, a group that is historically more likely to have higher disease burden and more quality-of-life impairments than patients without axial involvement.
The enteric nervous system (ENS) is comprised of the lining of the esophagus, stomach, small intestine, and colon and is estimated to include 500 million neurons and 40 neurotransmitters directly connected to mood and cognition. The newest research suggests that 95% of available serotonin and 50% of bio-available dopamine is produced in the ENS.
New research shows clinical effectiveness in increasing biologic doses in children, depending on the agent.
Rheumatology Network interviewed Hermine Brunner, MD, MSc, MBA, lead investigator of the JUNIPERA study, which reported on the safety and efficacy of secukinumab for patients with juvenile idiopathic arthritis (JIA), presented at the EULAR 2021 Virtual Congress. Secukinumab was the first approved biologic for specific JIA categories in the US and marked improvement of skin involvement with juvenile spondyloarthritis (jPSA) and increased quality of life for children with chronic arthritis plus psoriasis.
A new study builds upon previous insights and contributes to the growing trend of probiotic treatment in young patients.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 18, 2021.
A new study shows an increase in same or next day admissions in patients who opt for home infusions.
Investigators push for messaging transparency and consistency from health care professionals in regard to arthritis medication.
In patients with psoriatic arthritis (PsA), guselkumab (Tremfya, Janssen Immunology) treatment reduced serum protein levels of acute phase and T-helper cell 17 (Th17) effector cytokines, achieving comparable levels to those in healthy controls.
The risk was generally did not depend on whether the initial fracture was deemed traumatic or nontraumatic.
An analysis of data from more than 1000 women in Australia suggests each incremental increase in abdominal aortic calcification was linked to a 3% increase in risk of fall-related hospitalizations.
The American College of Rheumatology (ACR) published its long-awaited update to the 2015 Guidelines on the Management of Rheumatoid Arthritis last week. Have you read the 2021 update yet? Test your knowledge of the most important points with our quiz.
Investigators study loci and the hereditary nature of the disease, which was categorized as a global health priority by the WHO 3 years ago.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 11, 2021.
Liana Fraenkel, MD, MPH, discusses the recent updates to the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, for which she served as part of the Core Leadership Team.
Risankizumab showed significantly greater improvements in symptoms of psoriatic arthritis when compared with a placebo and was well tolerated in patients who were intolerant to biologics and conventional synthetic disease-modifying antirheumatic drugs.
